Fact Source: Financial Supervisory Service DART / 2026-02-10
Disclosure Type: Additional Listing (Exercise of Stock Options)
💡 3-Second Summary
Celltrion will list an additional 87,292 common shares on February 13, 2026, following the exercise of stock options.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Type and Number of Shares to be Listed: 87,292 Registered Common Shares
- 173th Tranche: 6,838 shares
- 174th Tranche: 15,944 shares
- 175th Tranche: 18,928 shares
- 176th Tranche: 19,435 shares
- 177th Tranche: 13,664 shares
- 178th Tranche: 12,483 shares
- Issue Price per Share (Par Value: KRW 1,000):
- 173rd Tranche: KRW 79,311
- 174th Tranche: KRW 71,999
- 175th Tranche: KRW 156,285
- 176th Tranche: KRW 123,606
- 177th Tranche: KRW 156,746
- 178th Tranche: KRW 128,858
- Date of Issuance: January 26, 2026
- Dividend Base Date: January 1, 2026
- Method of Capital Increase: Exercise of stock options
- Listing Date: February 13, 2026
- Stock Number: 068270
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This additional listing disclosure represents a routine capital increase stemming from stock option exercises, marking a mechanical change in the company’s total outstanding shares. The injection of newly issued common stock introduces a minor dilution of equity ownership for existing shareholders and carries a potential impact of short-term selling pressure once these shares become tradeable.
From a structural financial perspective, because the issue prices across all tranches (ranging from KRW 71,999 to KRW 156,746) are significantly higher than the par value of KRW 1,000, the capital paid in excess of par value will be credited to the company’s capital surplus, slightly optimizing equity fundamentals. However, the total volume of 87,292 shares constitutes a fraction (approximately 0.04%) of Celltrion’s overall outstanding capital block, meaning it is mathematically insufficient to trigger structural pricing stress or devalue core fundamentals. Investors could logically view the upcoming February 13, 2026 listing date as a transient technical event rather than a systemic trend shift.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion’s latest share expansion represents a standard operational listing driven by the exercise of stock options. Since a notable portion of the tranches carries strike prices lower than historical trading ranges, certain holders may elect to lock in gains, presenting localized supply pressure post-February 13. Nonetheless, given that the total volume of 87,292 shares is minuscule relative to Celltrion’s liquidity depth and massive float, the aggregate supply friction will likely remain well-contained. Market participants should look past this minor equity adjustments and anchor their analysis on broader corporate milestones and core biopharmaceutical operational velocity.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
